*Coursehero stop saying missing information when I included everything*

using the photo of the da ta fill out the charts that I provided and

an swer these questions in sentences

1. Explain how u found sales
2. explain how u found percent of sale of op expenses (weight of each product)
3. explain how much each product produces (most to least profitable)
4. explain where money is allocated (which departments)

Department	2019 Annual Operating Expense	Time spent supporting Commercial products
Commercial	$200MM	100%
IT	$100MM	25%
Facilities	$150MM	0%
Finance	$25MM	20%
Human Resources	$75MM	10%

Table of Contents at high risk for progressing to severe COVID-l9 andfor hospitalization. The EUA is temporary and does not replace a formal Biologics License Application ("BLA") submission review and approval process. This use is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use, unless terminated or revoked sooner. See information regarding ongoing clinical trials of REGEN-COV below. Net Product Sales of Regenerorr-Discovered Products Net Product Year Ended December 31, Re 31121, by 2020 2019 2018 (In millions) Regeneron U.S. ROW Total U.S. ROW Total U.S. ROW Total EYLEA'a) U.S. $ 4,947.2 $ 2,961.5 $ 7,908.7 $ 4,644.2 $ 2,897.4 $ 7,541.6 $ 4,0767 $ 2,6689 :5 6,745.6 Dupixent (b) $ 3,226.2 $ 8186 $ 4,044.3 $ 1,8712 5 4444 $ 2,315.6 $ 776.3 s 145.7 :3 922.0 Libtayom U.S. $ 270.7 5 77.5 $ 348.2 $ 175.7 $ 18.1 $ 193.8 5 14.8 $ 14.8 Praluent\") U.S. $ 186.0 5 172.8 33 358.8 $ 126.0 5 162.7 5 288.7 5 181.3 $ 125.5 33 306.8 Kevzara (b) 5 141.6 5 128 3 $ 269.9 95 129.0 $ 77.7 $ 206.7 5 74.7 $ 21.9 $ 96.6 REGEN-COVM) U.S. 5 185.7 $ 185.7 ZALTRAP (b) S 5.8 S 97 9 $ 103.7 95 7.3 $ 101.1 $ 108.4 5 9.0 $ 98.8 $ 107.8 ARCALYST U.S. $ 13.1 $ 13.1 $ 14.5 7 $ 14.5 $ 14.7 7 $ 14.7 ('3 Regeneron records net product sales of EYLEA in the United States. Bayer records net product sales of EYLEA outside the United States. The Company records its share of profits/losses in connection with sales of EYLEA outside the United States within Bayer collaboration revenue. 0'] Regeneron records net product sales of Libtayo in the United States. Sanofi records net product sales of Libtayo outside the United States and global net product sales of Dupixent, Kevzara, and ZALTRAP. The Company records its share of profitsflosses within Sanofi collaboration revenue in connection with (1) sales of Libtayo outside the United States, and (ii) global sales of Dupixent and Kevzara. Sanofi pays the Company a percentage of net sales of ZALTRAP. ('3 Effective April 1, 2020, Regeneron records net product sales of Praluent in the United States. Also effective April 1, 2020, Sanofi records net product sales of Praluent outside the United States and pays the Company a royalty on such sales. Previously, Sanofi recorded global net product sales of Praluent and the Company recorded its share of profits/losses in connection with such sales within Sanofi collaboration revenue. Refer to "Products" section above and "Collaboration, License, and Other Agreements - Sanofi" section below for further details. ('11 Regeneron records net product sales of REGEN-COV in connection with its agreements with the U.S. goverru'nent. Refer to "Agreements Related to COVID-lB U.S. Government" below for further details, Programs in Clinical Development Product candidates in clinical development, which are being developed by us andfor our collaborators, are summarized in the table below. We believe that our ability to develop product candidates is enhanced by the application of our VelociSuire technology platforms (refer to "Research and Development Technologies - VelociSuite" section below). We continue to invest in the development of enabling technologies to assist in our efforts to identify, develop, manufacture, and commercialize new product candidates. There are numerous uncertainties associated with drug development, including uncertainties related to safety and efficacy data from each phase of drug development (including any postapproval studies), uncertainties related to the enrollment and performance of clinical trials, changes in regulatory requirements, changes to drug pricing and reimbursement regulations and requirements, and changes in the competitive landscape affecting a product candidate. The planning, execution, and results of our clinical programs are significant factors that can affect our operating and financial results. We and our collaborators conduct clinical trials in multiple countries across the world. The COVID19 pandemic and the restrictions adopted around the globe to reduce the spread of the disease have impacted and will continue to impact our clinical development programs. We continue to evaluate the impact of the COVID19 pandemic on an individual trial basis and oversee trial management while also working to ensure patient safety and provide sufficient supply of product candidates for the studies. At this time, we expect fully enrolled clinical studies to remain generally on track. However, the ongoing pandemic continues to impact clinical trial execution in many regions across the world for us and our collaborators. The ultimate impact (including possible delays in recruiting andfor obtaining data) resulting from the COVIDl9 pandemic will depend, among other factors, on the extent of the pandemic in the areas with study sites and patient populations. It is possible that the COVID19 pandemic may cause clinical disruptions beyond those we have described. In addition, there may be delays in the timing of regulatory review and other projected milestones discussed in the table below